References of "Reginster, Jean-Yves"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailCan new information and communication technologies help in the management of osteoporosis ?
Slomian, Justine ULg; Appelboom, G; Ethgen, Olivier ULg et al

in Women's Health (2014), 10(3), 229-232

Detailed reference viewed: 16 (2 ULg)
Full Text
Peer Reviewed
See detailChallenges for the Development of Bone-Forming Agents in Europe.
Kanis, John A.; Rizzoli, Rene; Cooper, Cyrus et al

in Calcified tissue international (2014), 94

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailCurrent challenges in the treatment of osteoporosis: an opportunity for bazedoxifene.
Reginster, Jean-Yves ULg; Ferrari, Serge; Hadji, Peyman

in Current medical research and opinion (2014), 30(6), 1165-1176

Abstract Background: Osteoporosis affects millions of postmenopausal women worldwide. Osteoporosis-related fractures can lead to chronic pain, disability, systemic complications, and increased risk of ... [more ▼]

Abstract Background: Osteoporosis affects millions of postmenopausal women worldwide. Osteoporosis-related fractures can lead to chronic pain, disability, systemic complications, and increased risk of recurrent fractures, resulting in increased healthcare costs and mortality. Because currently available therapies have unique benefit/risk profiles, challenges remain in selecting the most appropriate treatment for each osteoporotic woman. Research and Results: Bazedoxifene (BZA), a new selective estrogen receptor modulator, is being developed for postmenopausal osteoporosis. In a 3-year, global, phase 3 study, BZA significantly reduced the risk of new vertebral fractures and nonvertebral fractures in women with higher baseline fracture risk compared with placebo. In 2 extensions of this study, the efficacy of BZA in reducing vertebral fracture risk was sustained over 7 years. BZA improved lumbar spine and total hip bone mineral density compared with placebo at 3 and 5 years, and demonstrated a favorable safety/tolerability profile, with no endometrial or breast stimulation. BZA was cost-effective compared with raloxifene in a 3-year, head-to-head comparative trial. Indirect comparisons further suggest that BZA may be as effective as bisphosphonates in reducing risk of nonvertebral fractures in women at high risk of fracture. BZA demonstrated efficacy and safety for treating postmenopausal osteoporosis over 7 years, particularly in women at a higher fracture risk. Conclusion: Because of its specific pharmacologic profile, BZA may be appropriate for postmenopausal women seeking a tolerable, safe, effective, and cost-effective long-term osteoporosis treatment. [less ▲]

Detailed reference viewed: 18 (6 ULg)
Full Text
Peer Reviewed
See detailA Critical Assessment of Approaches to Outpatient Monitoring.
Appelboom, Geoff; Sussman, Eric S.; Raphael, Pierre et al

in Current medical research and opinion (2014)

Abstract N/A.

Detailed reference viewed: 20 (7 ULg)
Full Text
Peer Reviewed
See detailThe promise of wearable activity sensors to define patient recovery.
Appelboom, Geoff; Yang, Annie H.; Christophe, Brandon R. et al

in Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia (2014), 21

The recent emergence of mobile health - the use of mobile telecommunication and wireless devices to improve health outcomes, services, and research - has inspired a patient-centric approach to monitor ... [more ▼]

The recent emergence of mobile health - the use of mobile telecommunication and wireless devices to improve health outcomes, services, and research - has inspired a patient-centric approach to monitor health metrics. Sensors embedded in wearable devices are utilized to acquire greater self-knowledge by tracking basic parameters such as blood pressure, heart rate, and body temperature as well as data related to exercise, diet, and psychological state. To that end, recent studies on utilizing wireless fitness activity trackers to monitor and promote functional recovery in patients suggest that collecting up-to-date performance data could help patients regain functional independence and help hospitals determine the appropriate length of stay for a patient. This manuscript examines existing functional assessment scales, discusses the use of activity tracking sensors in evaluating functional independence, and explores the growing application of wireless technology in measuring and promoting functional recovery. [less ▲]

Detailed reference viewed: 25 (12 ULg)
Full Text
Peer Reviewed
See detailFacteurs de risque de chute chez des sujets résidant en maison de repos : étude prospective d'une durée de 2 ans
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 164-165

Detailed reference viewed: 21 (8 ULg)
Full Text
Peer Reviewed
See detailFacteurs pronostiques de décès chez des sujets résidant en maison de repos suivis d'une manière prospective pendant une période de 2 ans
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 73-74

Detailed reference viewed: 10 (4 ULg)
Full Text
Peer Reviewed
See detailEvolution sur deux ans des capacités fonctionnelles et motrices de sujets âgés résidant en maison de repos
Buckinx, Fanny ULg; Beaudart, Charlotte ULg; Slomian, Justine ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 57-58

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailEvaluation de la prévalence de la sarcopénie selon différents outils de diagnostic
Beaudart, Charlotte ULg; SLANGEN, Catherine ULg; Buckinx, Fanny ULg et al

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 42

Detailed reference viewed: 18 (5 ULg)
Full Text
Peer Reviewed
See detailVitamine D et sujet âgé
Bruyère, Olivier ULg; Reginster, Jean-Yves ULg

in Gériatrie et Psychologie Neuropsychiatrie du Vieillissement (2014), 12(1), 5-6

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailPrevalence of vitamin D inadequacy in European women aged over 80 years
Bruyère, Olivier ULg; Slomian, Justine ULg; Beaudart, Charlotte ULg et al

in Archives of Gerontology & Geriatrics (2014)

Inadequate vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the ... [more ▼]

Inadequate vitamin D status is associated with secondary hyperparathyroidism and increased bone turnover and bone loss, which in turn increases fracture risk. The objective of this study is to assess the prevalence of inadequate vitamin D status in European women aged over 80 years. Assessments of serum 25-hydroxyvitamin D levels (25(OH)D) were performed on 8532 European women with osteoporosis or osteopenia of which 1984 were aged over 80 years. European countries included in the study were: France, Belgium, Denmark, Italy, Poland, Hungary, United Kingdom, Spain and Germany. Two cut-offs of 25(OH)D inadequacy were fixed: <75 nmol/L (30 ng/ml) and <50 nmol/L (20 ng/ml). Mean (SD) age of the patients was 83.4 (2.9) years, body mass index was 25.0 (4.0) kg/m2 and level of 25(OH)D was 53.3 (26.7) nmol/L (21.4 [10.7] ng/ml). There was a highly significant difference of 25(OH)D level across European countries (p < 0.0001). In these women aged over 80 years, the prevalence of 25(OH)D inadequacy was 80.9% and 44.5% when considering cut-offs of 75 and 50 nmol/L, respectively. In the 397 (20.0%) patients taking supplemental vitamin D with or without supplemental calcium, the mean serum 25(OH)D level was significantly higher than in the other patients (65.2 (29.2) nmol/L vs. 50.3 (25.2) nmol/L; P < 0.001). This study indicates a high prevalence of vitamin D (25(OH)D) inadequacy in old European women. The prevalence could be even higher in some particular countries. [less ▲]

Detailed reference viewed: 23 (11 ULg)
Full Text
Peer Reviewed
See detailStrontium ranelate decreases the number of rapid radiological progressors from the first year in SEKOIA study
Chevalier, X; Richette, P; Bruyère, Olivier ULg et al

in Osteoarthritis and Cartilage (2014), 22(1), 461

Detailed reference viewed: 9 (2 ULg)
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on knee osteoarthritis progression in the SEKOIA study
Eymard, F; Edwards, M; Parsons, C et al

in Osteoarthritis and Cartilage (2014), 22(1), 376

Detailed reference viewed: 6 (2 ULg)
Full Text
Peer Reviewed
See detailPatients' preferences for osteoporosis drug treatment: a discrete-choice experiment.
Hiligsmann, Mickaël ULg; Dellaert, Benedict G.; Dirksen, Carmen D. et al

in Arthritis research & therapy (2014), 16(1), 36

INTRODUCTION: The patient's perspective is becoming increasingly important in clinical and policy decisions. In this study, we aimed to evaluate the preferences of patients with, or at risk of ... [more ▼]

INTRODUCTION: The patient's perspective is becoming increasingly important in clinical and policy decisions. In this study, we aimed to evaluate the preferences of patients with, or at risk of, osteoporosis for medication attributes, and to establish how patients trade between these attributes. METHODS: A discrete choice experiment survey was designed and patients were asked to choose between two hypothetical unlabelled drug treatments (and an opt-out option) that vary in five attributes: efficacy in reducing the risk of fracture, type of potential common side-effects, mode and frequency of administration and out-of-pocket costs. An efficient experimental design was used to construct the treatment option choice sets and a mixed logit panel data model was used to estimate patients' preferences and trade-offs between attributes. RESULTS: A total of 257 patients with, or at risk of, osteoporosis completed the experiment. As expected, patients preferred treatment with higher effectiveness and lower cost. They also preferred either an oral monthly tablet or 6-month subcutaneous injection above weekly oral tablets, 3-month subcutaneous, 3-month intravenous or yearly intravenous injections. Patients disliked being at risk of gastro-intestinal disorders more than being at risk of skin reactions and flu-like symptoms. There was significant variation in preferences across the sample for all attributes except subcutaneous injection. CONCLUSIONS: This study revealed that osteoporotic patients preferred 6-month subcutaneous injection and oral monthly tablet, and disliked gastro-intestinal disorders. Moreover, patients were willing to pay a personal contribution or to trade treatment efficacy for better levels of other attributes. Preferences for treatment attributes varied across patients and this highlights the importance of clinical decision-making taking individual preferences into account to improve osteoporosis care. [less ▲]

Detailed reference viewed: 15 (5 ULg)
Full Text
Peer Reviewed
See detailRomosozumab in Postmenopausal Women with Low Bone Mineral Density.
McClung, Michael R.; Grauer, Andreas; Boonen, Steven et al

in The New England journal of medicine (2014), 370

Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. Methods In a phase 2, multicenter ... [more ▼]

Background Sclerostin is an osteocyte-derived inhibitor of osteoblast activity. The monoclonal antibody romosozumab binds to sclerostin and increases bone formation. Methods In a phase 2, multicenter, international, randomized, placebo-controlled, parallel-group, eight-group study, we evaluated the efficacy and safety of romosozumab over a 12-month period in 419 postmenopausal women, 55 to 85 years of age, who had low bone mineral density (a T score of -2.0 or less at the lumbar spine, total hip, or femoral neck and -3.5 or more at each of the three sites). Participants were randomly assigned to receive subcutaneous romosozumab monthly (at a dose of 70 mg, 140 mg, or 210 mg) or every 3 months (140 mg or 210 mg), subcutaneous placebo, or an open-label active comparator - oral alendronate (70 mg weekly) or subcutaneous teriparatide (20 mug daily). The primary end point was the percentage change from baseline in bone mineral density at the lumbar spine at 12 months. Secondary end points included percentage changes in bone mineral density at other sites and in markers of bone turnover. Results All dose levels of romosozumab were associated with significant increases in bone mineral density at the lumbar spine, including an increase of 11.3% with the 210-mg monthly dose, as compared with a decrease of 0.1% with placebo and increases of 4.1% with alendronate and 7.1% with teriparatide. Romosozumab was also associated with large increases in bone mineral density at the total hip and femoral neck, as well as transitory increases in bone-formation markers and sustained decreases in a bone-resorption marker. Except for mild, generally nonrecurring injection-site reactions with romosozumab, adverse events were similar among groups. Conclusions In postmenopausal women with low bone mass, romosozumab was associated with increased bone mineral density and bone formation and with decreased bone resorption. (Funded by Amgen and UCB Pharma; ClinicalTrials.gov number, NCT00896532 .). [less ▲]

Detailed reference viewed: 35 (6 ULg)
Full Text
Peer Reviewed
See detailEight years of denosumab treatment in postmenopausal women with osteoporosis: results from the first five years of the freedom extension
Papapoulos, S; Lippuner, K; Roux, C et al

in Osteoporosis International (2014), 25(2), 46-47

Detailed reference viewed: 25 (2 ULg)
Full Text
Peer Reviewed
See detailCould internet use be promising in health prevention and promotion in menopausal women ? A preliminary report
Slomian, Justine ULg; Streel, Sylvie ULg; Appleboom, G et al

in Osteoporosis International (2014), 25(2), 309

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailImpact of components of the metabolic syndrome on progression of knee osteoarthritis in the Sekoia study
Parsons, C; Edwards, MH; Eymard, F et al

in Osteoporosis International (2014), 25(2), 230

Detailed reference viewed: 11 (2 ULg)